Free shipping on all orders over $ 500

Lck inhibitor 2 

Cat. No. M30952

All AbMole products are for research use only, cannot be used for human consumption.

Lck inhibitor 2  Structure

Price and Availability

For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.


Quality Control & Documentation
Biological Activity

Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively IC50 Value: 13 nM(Lck) [1] Target: Src family kinase Lck inhibitor 2(Compound 9) inhibited 48 kinases with %control < 1 (33 of them tyrosine kinases, almost half of the 71 tyrosine kinases in the panel). A further 27 kinases were bound with %control < 10. Kd values for 16 kinases were determined and found to be below 100 nM. These included TXK (10 nM).

Chemical Information
Molecular Weight 335.36
Formula C18H17N5O2
CAS Number 944795-06-6
Form Solid
Solubility (25°C) DMSO 20 mg/mL (ultrasonic)
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Gabrielle Leclercq, et al. J Immunother Cancer. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

[2] Leora R Feldstein, et al. N Engl J Med. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

[3] Xiaomo Wu, et al. Comput Struct Biotechnol J. Application of PD-1 Blockade in Cancer Immunotherapy

[4] Laura R Saslow, et al. Nutr Diabetes. Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes

[5] Senthil Selvaraj, et al. Circulation. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF

Related Src-bcr-Abl Products
AP24534

Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor of BCR-ABL, PDGFRα, c-Src, c-Kit, FGFR and VEGFR.

Saracatinib

Saracatinib (AZD0530) is an orally active small molecule Src inhibitor.

Bosutinib

Bosutinib (SKI-606) is a novel Bcr-Abl inhibitor with IC50 values of 0.1 to 0.3 umol/L.

Dasatinib

Dasatinib (BMS-354825) is a small molecule inhibitor of both the SRC and BCR/ABL tyrosine kinases, with IC50's for the isolated kinases of 0.55 and 3.0 nM, respectively.

DCC-2036

DCC-2036 is an ABL inhibitor with IC50 of 0.8 and 2 nM for u-ABL1native and p-ABL1native, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: Lck inhibitor 2  supplier, Src-bcr-Abl, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.